Effect of MMP2 Expression on Cell Sensitivity to PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer Cells

doi:10.3870/j.issn.1672-8009.2026.02.008

Abstract

Abstract: Objective To investigate the effect of matrix metalloproteinase 2(MMP2)on the sensitivity of poly-ADP ribose polymerase inhibitor(PARPi)in high-grade serous ovarian cancer(HGSOC)cells and the underlying mechanism.Methods The HGSOC cell line HeyA8 cells were divided into 3 groups:control group,sh-NC group,sh-MMP2 group.RT-qPCR and Western blotting were used to detect the expression of MMP2.CCK-8 method was used to detect the cell survival rate under different concentrations of Olaparib.Then HeyA8 cells were divided into 4 groups:sh-NC group,sh-MMP2 group,sh-NC+PARPi group,sh-MMP2+PARPi group.Wound-healing assay,Annexin V-FITC/PI method and Hochest 33258 staining were used to detect cell migration and apoptosis,respectively.Western blotting was used to determine the expression levels of proteins related to the vascular endothelial growth factor(VEGF)/phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt).Results Compared with those in the control group and the sh-NC group,the relative expression levels of MMP2 mRNA and protein of HeyA8 cells in the sh-MMP2 group were downregulated,and the cell survival rate after Olaparib treatment was reduced(P<0.05).Compared with those in the sh-NC group,the wound-healing rate of HeyA8 cells in the sh-MMP2 group was decreased,the apoptosis rate was increased,nuclear condensation and fragmentation of apoptotic cells were observed,the relative protein expression levels of vascular endothelial growth factor A(VEGFA),vascular endothelial growth factor receptor 2(VEGFR-2),phosphorylated PI3K(Tyr458)[p-PI3K(Tyr458)]and phosphorylated Akt(Ser473)[p-Akt(Ser473)]were all downregulated(P<0.05).Compared with those in the sh-NC+PARPi group,the wound-healing rate of HeyA8 cells in the sh-MMP2+PARPi group was decreased,the apoptosis rate was increased,more apoptotic cells with nuclear condensation and fragmentation were observed,the relative protein expression levels of VEGFA,VEGFR2,p-PI3K(Tyr458)and p-Akt(Ser473)were downregulated(P<0.05).Conclusion Silencing MMP2 expression can promote PARPi-induced apoptosis in HGSOC cells,and increase PARPi sensitivity.

Key words: high-grade serous ovarian cancer, matrix metalloproteinase 2, olaparib, drug sensitivity, vascular endothelial growth factor/phosphatidylinositol 3-kinase/protein kinase B pathway

CLC Number:

R737.31

SHAO Ping, DENG Qingchun. Effect of MMP2 Expression on Cell Sensitivity to PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer Cells[J]. Journal of Medical Molecular Biology, 2026, 23(2): 164-170.

References

[1] SIDERIS M,MENON U,MANCHANDA R.Screening and prevention of ovarian cancer[J].Med J Aust,2024,220(5):264-274.
[2] REVYTHIS A,LIMBU A,MIKROPOULOS C,et al.Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer[J].Int J Environ Res Public Health,2022,19(14):8577.
[3] WILCZYŃSKI J,PARADOWSKA E,WILCZYŃSKI M.High-grade serous ovarian cancer-a risk factor puzzle and screening fugitive[J].Biomedicines,2024,12(1):229.
[4] BUONAIUTO R,NEOLA G,CALTAVITURO A,et al.Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type[J].Front Oncol,2024,14:1412807.
[5] CORDANI N,BIANCHI T,AMMONI L C,et al.An overview of PARP resistance in ovarian cancer from a molecular and clinical perspective[J].Int J Mol Sci,2023,24(15):11890.
[6] 何涛,周艳.血清VEGF、MMP-2水平与上皮性卵巢癌患者淋巴结转移的相关性[J].医药论坛杂志,2022,43(2):85-88.
HE T,ZHOU Yan.Correlation between Serum VEGF and MMP-2 levels and lymph node metastasis in patients with epithelial ovarian cancer[J].J Med Forum,2022,43(2):85-88.
[7] BURDETT N L,WILLIS M O,PANDEY A,et al.Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer[J].Sci Rep,2023,13(1):21884.
[8] ESCALONA R M,KANNOURAKIS G,FINDLAY J K,et al.Expression of TIMPs and MMPs in ovarian tumors,ascites,ascites-derived cells,and cancer cell lines:Characteristic modulatory response before and after chemotherapy treatment[J].Front Oncol,2022,11:796588.
[9] COLLET L,HANVIC B,TURINETTO M,et al.BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer:State of the art and forthcoming challenges[J].Front Oncol,2024,14:1354427.
[10] 孟新源,尹骏,张莉.奥拉帕利在铂敏感复发性卵巢癌患者维持治疗中疗效分析[J].临床军医杂志,2023,51(8):818-820.
MENG X Y,YIN J,ZHANG L.Analysis of the Efficacy of olaparib in maintenance therapy for platinum-sensitive recurrent ovarian cancer patients[J].Clin J Med Offic,2023,51(8):818-820.
[11] WANG C,GAO P,XU J,et al.Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment[J].Front Pharmacol,2022,13:1078303.
[12] KULKARNI S,GAJJAR K,MADHUSUDAN S.Poly(ADP-ribose)polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer[J].Front Oncol,2024,14:1414112.
[13] JIANG H,LI H.Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer:a systematic review and meta-analysis[J].BMC Cancer,2021,21(1):149.
[14] 江鲜雨,裴世敏.肿瘤疾病中MMP2与MMP9作为液体活检的生物标志物[J].现代畜牧兽医,2022(4):84-87.
JIANG X Y,PEI S X.MMP2 and MMP9 as biomarkers of liquid biopsy in tumor diseases[J].Mod J Anim Husb Vet Med,2022(4):84-87.
[15] WANG M,ZHANG S.miR-145 on the proliferation of ovarian cancer cells by regulating the expression of MMP-2/MMP-9[J].Cell Mol Biol,2022,67(6):141-148.
[16] MOMEN RAZMGAH M,GHAHREMANLOO A,JAVID H,et al.The effect of substance P and its specific antagonist(aprepitant)on the expression of MMP-2,MMP-9,VEGF,and VEGFR in ovarian cancer cells[J].Mol Biol Rep,2022,49(10):9307-9314.
[17] BASSIOUNI W,ALI M A M,SCHULZ R.Multifunctional intracellular matrix metalloproteinases:Implications in disease[J].FEBS J,2021,288(24):7162-7182.
[18] GHALEHBANDI S,YUZUGULEN J,PRANJOL M Z I,et al.The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF[J].Eur J Pharmacol,2023,949:175586.
[19] ELEBIYO T C,ROTIMI D,EVBUOMWAN I O,et al.Reassessing vascular endothelial growth factor(VEGF)in anti-angiogenic cancer therapy[J].Cancer Treat Res Commun,2022,32:100620.
[20] SHI B,XU F F,XIANG C P,et al.HIF1α/VEGF feedback loop contributes to 5-fluorouracil resistance[J].Front Pharmacol,2022,13:851401.
[21] HOXHAJ G,MANNING B D.The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism[J].Nat Rev Cancer,2020,20(2):74-88.
[22] SHI Y Y,MENG X T,XU Y N,et al.Role of FOXO protein’s abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer[J].J Obstet Gynaecol Res,2021,47(6):1946-1957.
[23] QIN Y C,YAN X,YUAN X L,et al.Osteopontin promotes gastric cancer progression via phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway[J].World J Gastrointest Oncol,2023,15(9):1544-1555.
[24] CHEN L,QING J,XIAO Y,et al.TIM-1 promotes proliferation and metastasis,and inhibits apoptosis,in cervical cancer through the PI3K/AKT/p53 pathway[J].BMC Cancer,2022,22(1):370.